• Publications
  • Influence
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
BACKGROUND Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronaryExpand
  • 4,249
  • 137
  • PDF
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.
BACKGROUND Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aortic-valveExpand
  • 2,458
  • 79
  • PDF
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of
The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines was formed to make recommendations regarding the diagnosis and treatment of patients withExpand
  • 2,441
  • 63
  • PDF
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODSExpand
  • 1,232
  • 61
  • PDF
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplateletExpand
  • 1,032
  • 57
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
CONTEXT The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested duringExpand
  • 1,124
  • 43
  • PDF
Endothelial dysfunction.
Drs Ganz and Vita 1 and Verma, Buchanan, and Anderson2 have presented persuasive evidence that endothelial function is dynamically regulated and that the endothelium’s vasodilator, antiinflammatory,Expand
  • 798
  • 36
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association
Preamble......971 I. Introduction ......972 A. Organization of Committee and Evidence Review......972 B. Purpose of These Guidelines......973 C. Overview of the Acute CoronaryExpand
  • 932
  • 35
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
BACKGROUND In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistentExpand
  • 490
  • 29
  • PDF
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of
The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the management of unstable angina and non–ST-segment elevation myocardial infarction (UA/NSTEMI) wereExpand
  • 2,618
  • 25
  • PDF